PYC THERAPEUTICS LIMITED (PYC)
Share Price Analysis and Chart

17/03/2026

1

Speculative Buy

$2.30

94.92%

PYC Therapeutics has provided key elements of a phase 3 trial design for its novel drug candidate, VP-001, to the US FDA, with key details aligned with FDA guidelines.

Bell Potter notes the "takeaway" for investors is the fact the randomised phase 3 trial will be long, likely four years in duration.

Assuming the trial commences in 2027, the broker forecasts US approval and launch in 2032. Importantly the alignment with the FDA is a critical element for de-risking. 

Speculative Buy. Target unchanged at $2.30.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -5.30 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -8.90 cents.

09/06/2026

1

Buy

$2.84

140.68%

Canaccord Genuity maintains a Buy rating for PYC Therapeutics with a $2.84 target price following the disclosure of Novartis' Phase III trial design metrics for competitor asset farabursen.

The newly detailed global regulatory protocol incorporates an expanded sample size of approximately 950 patients alongside dual active dosing configurations to systematically de-risk clinical effect size assumptions.

Prolonged competitor commercialization timelines are considered highly beneficial by the broker, potentially allowing an accelerated opportunity to narrow the operational timing gap.

If early clinical candidate PYC-003 delivers clean biomarker data from early 2027 onwards, the structural investment thesis suggests a leaner, more precise development pathway.

Underlying financial modeling remains completely intact, driven by long-term peak US sales projection of US$3bn by FY35.